Pharvaris N.V. logo

Pharvaris N.V.

NASDAQ:PHVS

Overview | Financials
Company Name Pharvaris N.V.
Symbol PHVS
Currency USD
Price 16.6
Market Cap 904,585,460
Dividend Yield 0%
52-week-range 11.51 - 25.499
Industry Biotechnology
Sector Healthcare
CEO Mr. Berndt Axel Edvard Modig CPA, M.B.A., MBA
Website https://pharvaris.com

An error occurred while fetching data.

About Pharvaris N.V.

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft

Related Stocks

Gossamer Bio, Inc. logo

Gossamer Bio, Inc.

GOSS

1.11 USD

Kiniksa Pharmaceuticals, Ltd. logo

Kiniksa Pharmaceuticals, Ltd.

KNSA

27.36 USD

Rani Therapeutics Holdings, Inc. logo

Rani Therapeutics Holdings, Inc.

RANI

0.559 USD

Inogen, Inc. logo

Inogen, Inc.

INGN

6.425 USD

Relmada Therapeutics, Inc. logo

Relmada Therapeutics, Inc.

RLMD

0.75 USD

PMV Pharmaceuticals, Inc. logo

PMV Pharmaceuticals, Inc.

PMVP

0.878 USD

Aveanna Healthcare Holdings Inc. logo

Aveanna Healthcare Holdings Inc.

AVAH

5.33 USD

Financials

Numbers are in millions USD

Numbers are in millions USD